Next Generation Nutriceuticals
Food and Pharma convergence in disease prevention and personalized nutrition
| Price: £1,480.00 Approx $2,874.16 (USD) €2,210.54 (EUR) |
|
|---|---|
| Overview: | |
| Today, consumers are taking a more proactive approach to managing their health and the prevention of diet-related diseases, such as obesity, diabetes, cardiovascular and bone and joint diseases. Many of these diseases are at epidemic levels, and this combined with increasing patient power makes the prevention of these lifestyle diseases attractive markets for both the food and pharmaceutical industries to exploit. Next-Generation Nutraceuticals is a new report published by Business Insights that provides analysis of how the food and pharmaceutical industries are becoming more aligned in their approach to consumer health. This report assesses the changing regulatory landscape in addition to how the strategies of leading ingredients, food, drinks and pharmaceutical companies are evolving in the new consumer health marketplace. Understand how food and drinks manufacturers are applying genomic and proteomic technologies that are widely used in the pharmaceutical industry in order to create increasingly sophisticated functional food products with this new report. |
|
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr CL Barton / Publication Date: 1st December 2006
Contents:
Table of Contents
Next-Generation Nutraceuticals
Executive Summary 10
Food and pharmaceutical disease prevention 10
Functional food and drinks 11
Technologies for nutrigenomics 12
The regulatory landscape 13
Strategies of leading ingredient, food, drinks and pharma companies 14
Future challenges and opportunities 15
Chapter 1
Food and pharmaceutical disease
prevention 18
Summary 18
Introduction 19
The changing approach to the health burden 20
New technologies 22
Key convergent markets 22
Obesity 24
Epidemiology 24
Sales 25
Cardiovascular disease 27
Epidemiology 27
Sales 29
Diabetes 31
Epidemiology 31
Sales 31
Bone health 33
Epidemiology 33
Sales 34
Conclusions 36
Chapter 2
Functional food and drinks 38
Summary 38
Introduction 39
Functional food and drinks 40
Functional ingredients 40
Scientific evidence to support the health benefits of functional ingredients 42
Proving efficacy: pharma vs. food 44
Growth areas and product trends in the functional foods market 45
Heart health 47
Digestive health - Probiotics 50
Innovative ingredients aligning with pharma 53
Personalized nutrition 54
Conclusions 55
Chapter 3
Technologies for nutrigenomics 58
Summary 58
Introduction 59
Biomic technologies in the pharma industry 59
Pharma technologies in the food industry 61
Genomics 63
Genomics in personalized nutrition 64
Case study: Sciona Inc 66
Transcriptomics 69
Transcriptomics in the food industry 71
Case study: WellGen Inc. 72
Proteomics 74
Metabolomics 75
Case study: the INTERMAP study 76
Challenges to metabolomics in nutrition research 77
Growth and interest in metabolomics 77
Systems Biology 78
Nanotechnology delivering new ingredients 79
Conclusions 80
Chapter 4
The regulatory landscape 82
Summary 82
Introduction 83
Regulation of health claims for functional foods 83
Japan 84
United States 86
Health claims 87
Structure/function claims 88
Criticism of the FDA’s approach 89
Europe 90
Opportunities and threats of functional food regulation 91
The future of functional food regulation 93
Regulation of personalized dietary advice 94
Conclusions 95
Chapter 5
Strategies of leading ingredient,
food, drinks and pharma
companies 98
Summary 98
Introduction 99
Ingredient manufacturers 99
DSM 100
BASF 102
Chr. Hansen 103
Products 104
Research 105
Opportunities for the ingredients industry 106
Food and drinks manufacturers 107
Nestlé 107
Nestlé’s products 108
Research 110
The future for Nestlé 111
Unilever 111
Unilever’s products 112
Research 114
The future for Unilever 115
Ajinomoto 115
Research and the future for Ajinomoto 117
Danone 118
The future for Danone 120
Coca-Cola 120
Other food and drinks manufacturers 122
Pharma companies 123
Future trends for the food and pharma industries 127
Agribusiness 128
Alliances 129
Food-pharma alliances 129
Alliances with new technology companies 130
Alliances for nutrigenomic research 131
Conclusions 134
Chapter 6
Future challenges and
opportunities 136
Summary 136
Introduction 137
Opportunities and market drivers 137
Consumer demand 137
Incentives 138
Opportunities in developing markets 139
New product development opportunities 140
Marketing 141
Challenges 141
Scientific challenges 142
Furthering basic and applied research 142
Clinical testing of nutraceuticals 142
Defining health 143
Ethical, legal and societal concerns 144
Ethical concerns 144
Societal concerns 144
Privacy and human rights 145
Research practices in nutrigenomics 145
The regulatory framework 145
Conclusions 146
Chapter 7
Appendix 150
Bibliography 150
Index 157
Footnotes 159
List of Figures
Figure 1.1: Drivers of change in the food and pharma industries 19
Figure 1.2: Examples of food and pharma approaches to heart disease 21
Figure 1.3: A functional food pyramid 23
Figure 1.4: The role of food and pharmaceuticals in the healthcare continuum 23
Figure 1.5: Examples of obesity drugs in development 26
Figure 1.6: Global deaths from cardiovascular disease 27
Figure 1.7: Drugs in clinical development for CV disorders 30
Figure 2.8: Top US consumer health concerns, 2005 46
Figure 2.9: Nutrigen IQ3 Yogurt Drink 48
Figure 2.10: Right Direction Cookies 49
Figure 2.11: DanaCol with Omega-3 & Plant Sterols Dairy Drink 50
Figure 2.12: Calpis Aqua Nyusankin 51
Figure 2.13: Calpis Interbalance L-92 Lactic Acid Bacteria Drink 53
Figure 3.14: The ‘omics technologies: definitions 60
Figure 3.15: The ‘omics technologies 61
Figure 3.16: The Cellf™ Assessment Kit from Sciona 66
Figure 3.17: Pro-inflammatory metabolic pathways 73
Figure 3.18: Technologies used in proteomics 74
Figure 3.19: 1H NMR spectrum of urine showing functional windows 75
Figure 3.20: Large scale metabolomic screening of human populations: identifying outliers 76
Figure 4.21: Standardized qualifying language for qualified health claims 88
Figure 4.22: Examples of structure/function claims allowed on food labeling 89
Figure 5.23: Recent products launched that contain TEAVIGO™ 102
Figure 5.24: Development of new probiotic cultures at Chr. Hansen 105
Figure 5.25: Nestlé’s products by functional category, 2004-2006 108
Figure 5.26: Nestlé’s functional brands (2005) 109
Figure 5.27: Nestle NesVita Pro-Heart Probiotic Drink 110
Figure 5.28: Unilever’s products by functional category, 2004-2006 112
Figure 5.29: Flora Pro-Active Blood Pressure Mini Drink 113
Figure 5.30: Ajinomoto products by functional category, 2004-2006 115
Figure 5.31: Calpis Ameal S Maiasa Yasai (vegetable breakfast drink) 117
Figure 5.32: Danone’s products by functional category, 2004-2006 118
Figure 5.33: Danone Petit Danone Cheese Dessert 119
Figure 5.34: Coca-Cola’s products by functional category, 2004-2006 120
Figure 5.35: Enviga 121
Figure 5.36: Novartis’ Benefiber Clear Choice! Powder and Isocal Jelly Arg Jelly Dessert 126
Figure 6.37: Awareness and favorability towards personalized nutrition 138
List of Tables:
viii
List of Tables
Table 1.1: Number and percentage of overweight and obese adults by country, 2005-2010 (%
adult population) 24
Table 1.2: Size of the diet food and drinks market and the obesity pharmaceutical market,
(US$,m), 2005-2010 25
Table 1.3: Estimated prevalence of major cardiovascular diseases in the seven major markets,
2004 28
Table 1.4: Size of the food and drinks and pharmaceutical markets for heart health, (US$,m),
2005-2010 29
Table 1.5: Prevalence of type-2 diabetes in the 7 major markets, 2005-11 31
Table 1.6: Size of the pharmaceutical market for diabetes, (US$,m), 2005-2010 32
Table 1.7: Prevalence of Rheumatoid Arthritis based on population > 60 in the seven major
markets (000s), 2005–2010 33
Table 1.8: Prevalence of osteoporosis in men and women over 50 across the seven major markets,
2005 34
Table 1.9: Size of the food and drinks and pharmaceutical markets for bone health, (US$m),
2005-2010 35
Table 2.10: Functional ingredients 40
Table 2.11: Functional food ingredients (cont.) 41
Table 2.12: Examples of functional food ingredients and the scientific basis for health benefit
claims 43
Table 2.13: Functional food and drink sales by value ($m), 2005-2008 45
Table 3.14: Companies offering nutrigenetic testing and dietary advice, 2006 65
Table 3.15: Genetic variations screened by the Cellf™ Assessment Kit from Sciona, 2006 67
Table 3.16: How nutrients alter gene expression 69
Table 3.17: Examples of transcriptomics in nutritional biology and nutrigenomics 70
Table 3.18: Companies and research centres utilizing gene expression analysis for nutrigenomic
applications 71
Table 4.19: FOSHU functions and functional food components 85
Table 4.20: Generic health claims currently approved by the FDA 87
Table 4.21: Regulatory opportunities and threats in the functional foods industry 92
Table 5.22: Ajinomoto products containing AmealPeptide™ launched in Japan 116
Table 5.23: Recent functional food and drinks launches 122
Table 5.24: Some functional food and drink products launched by pharma companies 124
Table 5.25: Consortia involved in the International Nutrigenomics Network 132
Table 5.26: Examples of other collaborative nutrigenomic research projects 133
Table 6.27: Biomarkers for well-being and disease risk reduction 143